Connect Biopharma Holdings Limited
3580 Carmel Mountain Road, Suite 200
San Diego, California 92130
May 28, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Connect Biopharma Holdings Limited |
Registration Statement on Form F-3
File No. 333-295921
To the addressees set forth above:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Connect Biopharma Holdings Limited, respectfully requests that the effective date of the Registration Statement on Form F-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on June 1, 2026, or as soon as practicable thereafter.
The Registration Statement received a “no review” letter from the Commission. If you have any questions or require additional information, please contact Michael Sullivan, Esq. of Latham & Watkins LLP at (858) 523-3959. Thank you for your assistance and cooperation in this matter.
| Very truly yours, | ||
| CONNECT BIOPHARMA HOLDINGS LIMITED | ||
| By: | /s/ Jeff Cohn | |
| Jeff Cohn | ||
| General Counsel and Corporate Secretary | ||
| cc: | David Szekeres, Connect Biopharma Holdings Limited |
Michael Sullivan, Latham & Watkins LLP